ReviewDrugs2013
Pharmacotherapy for the core symptoms in autistic disorder: current status of the research.
Review in Drugs, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- The Use of the Clinical Global Impressions Scale in Psychosocial Interventions for Autism Characteristics: A Systematic Review.Autism : the international journal of research and practice · 2026Pooled it
- Memantine for autism spectrum disorder.The Cochrane database of systematic reviews · 2022Pooled it
- Acceptability, equity, and feasibility of using antipsychotics in children and adolescents with autism spectrum disorder: a systematic review.BMC psychiatry · 2020Pooled it
- Trial
- Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study.Nutrients · 2023Trial
- Effects of propranolol on conversational reciprocity in autism spectrum disorder: a pilot, double-blind, single-dose psychopharmacological challenge study.Psychopharmacology · 2016Trial
- Modulation of resting-state amygdala-frontal functional connectivity by oxytocin in generalized social anxiety disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Trial
- 12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Trial
- Patterns of Psychotropic Prescribing Practices in Autistic Children and Adolescents: An Australian Perspective of Two Cohorts Five Years Apart.Child psychiatry and human development · 2026Article
- Antipsychotic Treatment and Longitudinal Body Mass Index Trajectories in Youth with and Without Autism Spectrum Disorder.Journal of clinical medicine · 2026Article
- Targeting the P2X7 receptor signaling pathway: Unlocking therapeutic strategies for autism spectrum disorder.Brain, behavior, & immunity - health · 2025Review
- Gene expression differences in the olfactory bulb associated with differential social interactions and olfactory deficits in Pax6 heterozygous mice.Biology open · 2025Article
- Retrospective review: single- and multidonor washed microbiota transplantation have equivalent efficacy in the treatment of autism.Frontiers in cellular and infection microbiology · 2025Article
- Glucose transporter 1 deficiency, AMP-activated protein kinase activation and immune dysregulation in autism spectrum disorder: Novel biomarker sources for clinical diagnosis.Saudi journal of biological sciences · 2023Article
- Acetylcholinesterase inhibitors for autistic spectrum disorders.The Cochrane database of systematic reviews · 2023Review
- Oxytocin protective effects on zebrafish larvae models of autism-like spectrum disorder.Iranian journal of basic medical sciences · 2023Article
- Article
- Review
- BDNF, proBDNF and IGF-1 serum levels in naïve and medicated subjects with autism.Scientific reports · 2022Article
- Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications.Cannabis and cannabinoid research · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The current review covers extant literature on pharmacotherapy for core symptoms of autism. The core symptoms of autism include impairments in social interaction and communication, as well as the presence of restricted and repetitive behaviors. There are no known efficacious treatments for the core social symptoms, although effects on repetitive behaviors are indicated with some data. While studies of fenfluramine, secretin, opiates, and mood stabilizers generally find no effect, mixed results suggest more research is needed on antidepressants and atypical antipsychotics. Newer lines of research, including cholinergic and glutamatergic agents and oxytocin, will be of considerable interest in the future. However, research on the treatment of core symptoms is plagued by limitations in study design, statistical power, and other issues inherent to the study of treatments for autism (e.g., heterogeneity of the disorder) that continue to prevent the elucidation of efficacious treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.